Vnitr Lek 2018, 64(4):395-401 | DOI: 10.36290/vnl.2018.058

Dyslipidemia and hypertension - what to worry about more?

Jan Václavík
I. interní klinika - kardiologická LF UP a FN Olomouc

Dyslipidemia is present in every other patient with arterial hypertension. With increasing blood pressure and cholesterol levels, the risk of cardiovascular events increases proportionally. Treatment of dyslipidemia appears to lower cardiovascular mortality to a greater extent than treatment of hypertension. A significant proportion of patients with dyslipidemia indicated for drug therapy are not treated at all or treated insufficiently and do not reach the target values. Concurrent treatment of hypertension and dyslipidemia reduces the incidence of cardiovascular events significantly more than treating only one of these diseases. An even better efficacy of combined treatment of hypertension and dyslipidemia can be achieved by improving patient adherence using fixed drug combinations.

Keywords: arterial hypertension; cardiovascular events; dyslipidemia; fixed combinations; treatment

Received: February 6, 2018; Accepted: March 22, 2018; Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J. Dyslipidemia and hypertension - what to worry about more? Vnitr Lek. 2018;64(4):395-401. doi: 10.36290/vnl.2018.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>. Go to original source... Go to PubMed...
    2. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati). Eur Heart J 2016; 37(29): 2315-2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>. Go to original source... Go to PubMed...
    3. Widimský J, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze Kardiovask Prevence 2018; 7(Supplementum): 1-19.
    4. Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012; 2012: 925046. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/925046>. Go to original source... Go to PubMed...
    5. Wohlfahrt P, Krajčoviechová A, Bruthans J et al. Hypertension and hypercholesterolemia in the Czech population. Vnitř Lék 2016; 62(11): 863-867. Go to PubMed...
    6. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913. Erratum in Lancet 2003; 361(9362): 1060. Go to original source... Go to PubMed...
    7. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383(9932): 1899-1911. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(14)60685-1>. Go to original source... Go to PubMed...
    8. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2224-2260. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(12)61766-8>. Go to original source... Go to PubMed...
    9. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension 2017; pii: HYP.0000000000000065. <http://dx.doi.org/10.1161/HYP.0000000000000065>. Go to original source... Go to PubMed...
    10. Muntner P, Carey RM, Gidding S et al. Potential U.S. Population Impact of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. J Am Coll Cardiol 2018; 71(2): 109-118. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.10.073>. Go to original source... Go to PubMed...
    11. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532-2561. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(16)31357-5>. Erratum in Department of Error. [Lancet 2017]. Go to original source... Go to PubMed...
    12. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152(1): 56-64. Go to original source...
    13. Zhang X, Patel A, Horibe H et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32(4): 563-572. Go to original source... Go to PubMed...
    14. Jackson R, Lawes CMM, Bennett DA et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365(9457): 434-441. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(05)17833-7>. Go to original source...
    15. Hradec J, Bultas J, Kmínek A et al. Jak se léčí statiny v České republice? Výsledky průzkumu STEP. Cor Vasa 2011; 53(10): 527-534. Go to original source...
    16. Grover SA, Coupal L, Kaouache M et al. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia? Can J Cardiol 2007; 23(6): 467-473. Go to original source... Go to PubMed...
    17. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484-491. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ehj.2003.11.012>. Go to original source... Go to PubMed...
    18. Ference B, Ference T, Brook RD et al. A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease. ESC Congress 2016. Rome; 2016. FP Number: 3163.
    19. Kolandaivelu K, Leiden BB, O'Gara PT et al. Non-adherence to cardiovascular medications. Eur Heart J 2014; 35(46): 3267-3276. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu364>. Go to original source... Go to PubMed...
    20. Jin J, Sklar GE, Min Sen Oh V et al. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008; 4(1): 269-286. Go to original source...
    21. Fung V, Huang J, Brand R et al. Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clin Ther 2007; 29(5): 972-984. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinthera.2007.05.010>. Go to original source... Go to PubMed...
    22. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147-1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.10.1147>. Go to original source... Go to PubMed...
    23. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713-719. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2006.08.033>. Go to original source... Go to PubMed...
    24. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59(6): 1124-1131. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.194167>. Go to original source... Go to PubMed...
    25. Thom S, Poulter N, Field J et al. Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD. JAMA 2013; 310(9): 918. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.277064>. Erratum in JAMA 2013; 310(14): 1507. Go to original source... Go to PubMed...
    26. Lewington S, Whitlock G, Clarke R et al. [Prospective Studies Collaboration]. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-1839. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(07)61778-4>. Erratum in Lancet. 2008; 372(9635): 292. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.